ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Program Announcements For Tobacco Research

January 21, 1983

New Diet Trial Is Described In Concept

October 26, 1990

NIH Slow To Implement Equality In Studies, GAO Says, But Waxman Assures Reauthorization

June 22, 1990

Revlimid Plus Steroid Effective In Clinical Trial

November 30, 2007

In Brief: Mammography Quality assurance Act Introduced Laurence Marton Succeeds Brown At Wisconsin

November 1, 1991

In Brief: House Money Bill Reportedly Will Not Increase

September 18, 1981